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In 2008, melioidosis was diagnosed in an agricultural 
worker from Thailand in the southern Jordan Valley in Israel. 
He had newly diagnosed diabetes mellitus, fever, multiple 
abscesses, and osteomyelitis. Burkholderia pseudomallei 
was isolated from urine and blood. Four of 10 laboratory 
staff members exposed to the organism received chemo-
prophylaxis, 3 of whom had adverse events.
M
elioidosis, which is caused by Burkholderia pseudo-
mallei, is endemic to some areas of Southeast Asia 
and northern Australia (1,2). Recent data indicate that it is 
now endemic to most of the Indian subcontinent, southern 
People’s Republic of China, Hong Kong, Taiwan, Papua 
New Guinea, and other regions (3). Most cases reported in 
other regions were acquired during residence in or travel to 
disease-endemic regions.
Thailand is a popular destination for backpackers from 
Israel. Importation of melioidosis has long been antici-
pated as a potential problem because many persons from 
Thailand are employed in Israel. Although most infec-
tions are asymptomatic (2) and usually occur in persons 
<6 years of age in disease-endemic areas, clinical, often 
life-threatening, disease most frequently affects adults who 
have underlying predisposing conditions, especially type 2 
diabetes. Incubation period differs according to manner of 
exposure and size of inoculum and may be short (1 day 
to 2–3 weeks). However, because the organism has a pro-
clivity for latency (4), the disease may appear after months 
or many years (2,4). Melioidosis is often manifested as 
pneumonia, but its hallmark is disseminated abscess for-
mation in viscera, skin, soft tissue, and bone. We report 
a case of imported melioidosis (5) and management and 
consequences of chemoprophylaxis among laboratory staff 
exposed to B. pseudomallei.
The Case
A 32-year-old man from Thailand was referred to the 
emergency department of Hadassah–Hebrew University 
Hospital at Mount Scopus on July 31, 2008, with newly 
diagnosed diabetes and fever. He reported 2–3 weeks of 
fatigue, chills, night sweats, and a weight loss of ≈25 kg in 
the past 2 months. Two large subcutaneous abscesses had 
developed over the past several months. The ﬁ  rst abscess, 
in the right axilla, had been drained in May 2008. The sec-
ond abscess, in the upper right abdominal wall, had been 
drained in July 2008. Pus was not submitted for culture.
The patient, an agricultural worker, arrived in Israel 
in November 2007 and was employed at a rural settlement 
in the southern Jordan Valley. He came from a village in 
northeastern Thailand where he had worked in rice and 
sugar cane farming. At the time of admission, he appeared 
ill and was febrile (39.0°C). Physical examination showed 
mild cervical lymphadenopathy, nontender hepatomegaly, 
and healing wounds from the abscess drainage procedures. 
Laboratory results showed hyperglycemia (glucose level 
19.4 mmol/L), normocytic anemia with normal leukocyte 
and platelet counts, an erythrocyte sedimentation rate of 
105 mm/h, and moderately elevated levels of alkaline phos-
phatase and γ-glutamyl transferase. Kidney function was 
normal. Urinalysis showed leukocyturia and nitrites. Mul-
tiple abscesses were seen in the spleen, lungs, superior pole 
of the right kidney, prostate gland, and right foot (Figure). 
A bone scan conﬁ  rmed osteomyelitis of the right medial 
malleolus, calcaneus, and ﬁ  rst metatarsus.
A diagnosis of melioidosis had been considered from 
the outset in view of clinical ﬁ  ndings of multiple ab-
scesses in a patient with diabetes from a disease-endemic 
area. A blood culture (BacTec+ Aerobic/F; Becton, Dick-
inson and Company, Sparks, MD, USA) yielded a non-
fermentative, oxidase-positive, motile, colistin-resistant, 
gram-negative bacilli that showed dry wrinkled colonies. 
The API 20 NE proﬁ  le (API; bioMérieux, Durham, NC, 
USA) was 1556577, which suggested esculin-positive B. 
pseudomallei.
Molecular conﬁ  rmation was achieved by bidirectional 
sequencing of a 1.7-kb amplicon speciﬁ  c for the 16S rRNA 
gene, which was ampliﬁ  ed by PCR and primers F229 and 
R1908 (6). Sequencing (National Center for Biotechnology 
Information accession no. FJ426359) with the same prim-
ers showed the known single basepair transition (C/T) at 
position 75 that distinguishes B. pseudomallei from B. mal-
lei, the agent of glanders (6).
Susceptibility to trimethoprim/sulfamethoxazole was 
conﬁ  rmed. MICs were 0.75 mg/L for trimethoprim and 
14.25 mg/L for sulfamethoxazole (Etest; AB Biodisk, Sol-
na, Sweden). A urine culture was positive for B. pseudo-
mallei,  and throat and splenic abscess aspirate cultures 
were negative.
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DOI: 10.3201/eid1511.090038The patient’s ﬁ  rst abscess developed ≈6 months after 
his arrival in Israel, which attests to a long incubation period 
or prolonged latency after initial asymptomatic infection. 
New-onset diabetes might have unmasked a preexisting la-
tent infection. He had no history of an illness compatible 
with melioidosis before he left Thailand.
Treatment with ceftazidime (2 g intravenously 4×/d) 
and trimethoprim/sulfamethoxazole (1,920 mg orally 2×/d) 
for 4 weeks resulted in gradual defervescence. The patient 
was discharged with instructions to take trrimethoprim/
sulfamethoxazole (1,920 mg orally 2×/d) and doxycycline 
(100 mg orally 2×/d) for an additional 20 weeks. He re-
turned to Thailand a few weeks after discharge.
B. pseudomallei infection has been regarded as an 
occupational hazard for clinical microbiologists (7–9). 
Although risk for laboratory-acquired infection is rela-
tively low (7), the nature of the disease demands special 
precautions in dealing with its causative organism. With 
recent designation of B. pseudomallei as a select agent by 
the Centers for Disease Control and Prevention (www.cdc.
gov/od/sap), it has been proposed that Biosafety Level 2 
practices, which were advised for clinical diagnostic work 
(10), be replaced by stricter safety practices (11).
Accordingly, a risk assessment was performed, and 4 
persons who had handled the cultures outside a biologic 
safety cabinet were offered postexposure chemoprophy-
laxis with trimethoprim/sulfamethoxazole (1,920 mg orally 
every 8 h) for 3 weeks) (11). The frequency of rashes was 
worrisome: rashes developed in 2 persons (1 elected to com-
plete the course of doxycycline [100 mg orally 2×/d for 3 
weeks] and 1 stopped treatment after 10 days). One person 
was so uncomfortable that she refused further treatment on 
day 12. Only 1 person completed the course of trimethop-
rim/sulfamethoxazole without adverse effects. Symptoms 
consistent with melioidosis did not develop in any of the 
exposed staff. Serum samples from 10 staff members who 
had had any contact with the cultures were collected within 
2–3 days of exposure and after 6–8 weeks and tested by us-
ing an indirect hemagglutination test at Mahidol University 
in Bangkok. All serologic test results were negative, an out-
come consistent with ﬁ  ndings of a published report (8).
Conclusions
Many workers (10,600 in 2007) from Thailand have 
been employed in agriculture in Israel (12). Cases of me-
lioidosis may not have been detected until the present pa-
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Figure. Computed tomography images showing multiple abscesses in the right lung (A), spleen and upper pole of the right kidney (B), 
prostate gland (C), and plantar aspect of the right foot (D) (arrows) of the patient. Imported Melioidosis, Israel, 2008
tient because routine preemployment medical screenings 
may have excluded persons with the disease from entry 
into Israel or unfamiliarity with the disease led to under-
diagnosis.
Migration of populations requires awareness regard-
ing unforeseen diseases, as recently highlighted in a clini-
cal problem-solving exercise (13). If one considers the ab-
scesses in our patient, melioidosis would have likely been 
diagnosed earlier had this patient remained in Thailand. 
In any case, if the routine practice of culturing pus from 
his abscesses had been followed, the diagnosis might have 
been made earlier. This ﬁ  nding is a reminder to physicians 
that they should adhere to basic clinical guidelines. Con-
versely, clinical evidence and close cooperation of ward 
physicians, the infectious disease service, and the labora-
tory staff likely expedited identiﬁ  cation of the organism.
The diagnosis of melioidosis in a region where this 
disease is not endemic depends on physician awareness and 
laboratory capability. In the patient reported here, clinical 
suspicion, suggested by multiple visceral abscesses, pre-
ceded microbiologic conﬁ  rmation, which was expedited 
by internists and the infectious disease service. Clinical 
microbiology laboratories worldwide should prepare for 
dealing with B. pseudomallei and include it in the workup 
of unusual nonfermentative, colistin-resistant, gram-nega-
tive bacilli, particularly in workers from Thailand or other 
melioidosis-endemic countries. The issue of chemoprophy-
laxis for persons with laboratory exposures, and its poten-
tial for adverse events, requires careful immediate decision 
making, especially if one considers the rarity of this albeit 
disabling disease among laboratory staff.
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